▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3325 by analyst upside · 2026-06-27
HNGE
Hinge Health, Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+3.9%
implied upside to consensus target
Current Price $78.97
Consensus Target $82.07
Bull Target $125.0
Bear Target $65.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
8
Hold
1
Sell
0
52-Week Low $30.08
52-Week High $79.26
YTD Return +73.3%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E 23.5x
EPS (TTM) $-8.91
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $646M
Profit Margin -78.9%
52-WEEK RANGE
52-Week Low $30.08
52-Week High $79.26
Current Price $78.97
Bear Target $65.0
Bull Target $125.0
● Now $78.97 ● Target $82.07
TRADING DATA
Avg Volume 1.5M
YTD Return +73.3%
Analyst Count 15
Consensus Buy
Upside to Target +3.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Hinge Health, Inc. (HNGE) is currently trading at $78.97 with a Wall Street consensus price target of $82.07, implying potential upside of 3.9% over the next 12 months. 15 analysts currently cover HNGE, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $125.0, while the most cautious has a target of $65.0.

HNGE operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 73.3% year-to-date and is currently trading near the upper end of its 52-week range of $30.08 – $79.26.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CHE -3.6%
Chemed Corporation
$6B · P/E 24.7x · Hold
LNTH -4.2%
Lantheus Holdings, Inc.
$7B · P/E 26.0x · Buy
PACS +18.6%
PACS Group, Inc.
$7B · P/E 27.0x · Buy
INDV +21.2%
Indivior Pharmaceuticals, Inc.
$5B · P/E 21.2x · Buy
QGEN +11.6%
Qiagen N.V.
$8B · P/E 20.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for HNGE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Baird — Reiterated
Neutral → Neutral 2026-06-17 Building track record
Raymond James — Reiterated
Outperform → Outperform 2026-06-15 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-06-15 Building track record
Keybanc — Reiterated
Overweight → Overweight 2026-06-12 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-06-11 Building track record
Truist Securities — Reiterated
Buy → Buy 2026-06-11 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-06-11 Building track record
Needham — Reiterated
Buy → Buy 2026-06-11 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
21/30
Consensus clarity
15/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →